Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Following the landmark approval of imatinib 20 years ago, over 70 kinase inhibitors are now transforming the clinical care of multiple malignancies and a handful of other disorders.
